Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C
暂无分享,去创建一个
[1] Haesuk Park,et al. The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders , 2021, Journal of managed care & specialty pharmacy.
[2] R. Cook,et al. The Impact of Direct‐Acting Antiviral Therapy on End‐Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders , 2021, Hepatology.
[3] Joshua D. Brown,et al. Impact of hepatitis C virus treatment on the risk of non‐hepatic cancers among hepatitis C virus‐infected patients in the US , 2020, Alimentary pharmacology & therapeutics.
[4] T. Mattingly,et al. Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review , 2020, PharmacoEconomics.
[5] R. Feldman,et al. Association of Direct-Acting Antiviral Therapy for Hepatitis C With After-Treatment Costs Among Medicare Beneficiaries , 2020, JAMA network open.
[6] C. Stedman,et al. Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies: An international study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] Christine Y. Lu,et al. Cost burden of hepatitis C virus treatment in commercially insured patients. , 2019, The American journal of managed care.
[8] J. Dillon,et al. Impact of Hepatitis C treatment on behavioural change in relation to drug use in people who inject drugs: A systematic review. , 2019, The International journal on drug policy.
[9] J. Lazarus,et al. Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. , 2019, The International journal on drug policy.
[10] E. Wood,et al. Disparities in uptake of direct‐acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting , 2019, Liver international : official journal of the International Association for the Study of the Liver.
[11] S. Patel,et al. Behavioral Health Integration With Primary Care: Implementation Experience and Impacts From the State Innovation Model Round 1 States. , 2019, The Milbank quarterly.
[12] C. Latkin,et al. Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore. , 2019, Journal of substance abuse treatment.
[13] Haesuk Park,et al. Impact of All‐Oral Direct‐Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States , 2019, Hepatology.
[14] Andreina A Ottman,et al. Impact of Substance Use Disorder on the Rate of Sustained Virological Response in Veterans With Chronic Hepatitis C Treated With Direct-Acting Antivirals , 2019, The Annals of pharmacotherapy.
[15] Jonathan Mermin,et al. Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013‐2016 , 2018, Hepatology.
[16] T. Rhodes,et al. Caring and curing: Considering the effects of hepatitis C pharmaceuticalisation in relation to non-clinical treatment outcomes. , 2018, The International journal on drug policy.
[17] Alex H. S. Harris,et al. Applying American Society of Addiction Medicine Performance Measures in Commercial Health Insurance and Services Data , 2018, Journal of addiction medicine.
[18] B. Linas,et al. A Guide to the Economics of Hepatitis C Virus Cure in 2017. , 2018, Infectious disease clinics of North America.
[19] Z. Butt,et al. Identifying injection drug use and estimating population size of people who inject drugs using healthcare administrative datasets. , 2018, The International journal on drug policy.
[20] M. Socías,et al. Integrated Models of Care for People Living with Hepatitis C Virus and a Substance Use Disorder: Protocol for a Systematic Review , 2018, JMIR research protocols.
[21] P. Deb,et al. Modeling Health Care Expenditures and Use. , 2018, Annual review of public health.
[22] H. Masur,et al. Collocation of Buprenorphine with HCV treatment to improve adherence and reduce harm in PWID with HCV: Preliminary data from the ANCHOR study , 2018 .
[23] P. Read,et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. , 2018, The lancet. Gastroenterology & hepatology.
[24] W. Schaffner,et al. Epidemiology and risk factors for hepatitis C virus infection in a high-prevalence population , 2018, Epidemiology and Infection.
[25] G. Dore,et al. Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies , 2018, Open forum infectious diseases.
[26] Benjamin P Linas,et al. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. , 2018, Journal of substance abuse treatment.
[27] Dongmu Zhang,et al. Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] J. Yager,et al. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. , 2018, The American journal of psychiatry.
[29] Rahi Abouk,et al. Association of US State Implementation of Newborn Screening Policies for Critical Congenital Heart Disease With Early Infant Cardiac Deaths , 2017, JAMA.
[30] Likang Xu,et al. Annual surveillance report of drug-related risks and outcomes -- United States, 2017 , 2017 .
[31] S. Trudeau,et al. Validity of an automated algorithm using diagnosis and procedure codes to identify decompensated cirrhosis using electronic health records , 2017, Clinical epidemiology.
[32] D. Fierer,et al. Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection , 2017, Addictive disorders & their treatment.
[33] Minjun Chen,et al. Direct-Acting Antivirals for Chronic Hepatitis C: Can Drug Properties Signal Potential for Liver Injury? , 2017, Gastroenterology.
[34] N. Gupta,et al. Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. , 2017, Journal of substance abuse treatment.
[35] P. Gustafson,et al. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study. , 2017, The lancet. Gastroenterology & hepatology.
[36] J. Tor,et al. Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections , 2016, World journal of hepatology.
[37] T. Ayer,et al. Hepatitis C Disease Burden in the United States in the era of oral direct‐acting antivirals , 2016, Hepatology.
[38] D. Nickle,et al. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. , 2016, Annals of internal medicine.
[39] Christopher R. Taber,et al. Difference-in-Differences Method in Comparative Effectiveness Research: Utility with Unbalanced Groups , 2016, Applied Health Economics and Health Policy.
[40] D. Vlahov,et al. Clinicians' Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject Drugs , 2016, Substance use & misuse.
[41] Walid F. Gellad,et al. Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. , 2016, Addiction.
[42] T. Rhodes,et al. Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs. , 2015, The International journal on drug policy.
[43] M. Ciarleglio,et al. Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade , 2015, PloS one.
[44] S. Holmberg,et al. Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs , 2015, Annals of Internal Medicine.
[45] G. Dore,et al. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States , 2015, Annals of Internal Medicine.
[46] E. Stuart,et al. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies , 2015, Statistics in medicine.
[47] M. King,et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. , 2015, Journal of hepatology.
[48] Patrick B Ryan,et al. The impact of standardizing the definition of visits on the consistency of multi-database observational health research , 2015, BMC Medical Research Methodology.
[49] David S Goldberg,et al. Coding algorithms for identifying patients with cirrhosis and hepatitis B or C virus using administrative data , 2015, Pharmacoepidemiology and drug safety.
[50] A. Ryan,et al. Methods for evaluating changes in health care policy: the difference-in-differences approach. , 2014, JAMA.
[51] Elizabeth A. Stuart,et al. Using propensity scores in difference-in-differences models to estimate the effects of a policy change , 2014, Health Services and Outcomes Research Methodology.
[52] R J Glynn,et al. Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs , 2014, Journal of internal medicine.
[53] William H Crown,et al. Propensity-Score Matching in Economic Analyses: Comparison with Regression Models, Instrumental Variables, Residual Inclusion, Differences-in-Differences, and Decomposition Methods , 2014, Applied Health Economics and Health Policy.
[54] J. B. Layton,et al. Propensity Score Methods for Confounding Control in Nonexperimental Research , 2013, Circulation. Cardiovascular quality and outcomes.
[55] Bryan Dowd,et al. Interaction Terms in Nonlinear Models , 2002 .
[56] H. El‐Serag,et al. Insurance status and treatment candidacy of hepatitis C patients: Analysis of population‐based data from the United States , 2011, Hepatology.
[57] P. Austin. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.
[58] M. Raebel,et al. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[59] S. Mauss,et al. Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects. , 2008, Current drug abuse reviews.
[60] E. Vrettou,et al. Treatment of intravenous drug users with chronic hepatitis C: treatment response, compliance and side effects. , 2007, Hippokratia.
[61] Michal Abrahamowicz,et al. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. , 2005, American journal of epidemiology.
[62] E. Duflo,et al. How Much Should We Trust Differences-in-Differences Estimates? , 2001 .
[63] J. Mullahy. Specification and testing of some modified count data models , 1986 .
[64] D. Mosley,et al. Random assignment of proxy event dates to unexposed individuals in observational studies: An automated technique using SAS ® . , 2012 .
[65] 石黒 真木夫,et al. Akaike information criterion statistics , 1986 .